---
title: "SIPAI HEALTH's subsidiary plans to sell 100% equity of SIPAI Zhihe Technology (Guangzhou) for 51.73 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283688166.md"
description: "SIPAI HEALTH announced that its wholly-owned subsidiary SIPAI Investment will sell 100% equity of its wholly-owned subsidiary SIPAI Zhihe Technology (Guangzhou) to DSL for RMB 51.73 million. This transaction will result in SIPAI HEALTH no longer holding any equity in the target company, and the target company will no longer be its subsidiary. This move aims to optimize resource allocation, focus on core business, enhance overall gross margin, and accelerate the achievement of profitability goals"
datetime: "2026-04-22T14:48:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283688166.md)
  - [en](https://longbridge.com/en/news/283688166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283688166.md)
---

# SIPAI HEALTH's subsidiary plans to sell 100% equity of SIPAI Zhihe Technology (Guangzhou) for 51.73 million yuan

According to the announcement from SIPAI HEALTH (00314), on April 22, 2026, SIPAI Investment (a wholly-owned subsidiary of the company) (as the seller) entered into a share transfer agreement with DSL (as the buyer). Accordingly, SIPAI Investment conditionally agreed to sell all of its equity in the target company SIPAI Zhihe Technology (Guangzhou) Co., Ltd. (a wholly-owned subsidiary of the company) for a total consideration of RMB 51.73 million.

As part of the sale, the company will also transfer its equity in two subsidiaries, Siwei Te and Beijing Renbo, to the target company, which will also constitute part of the target group to be sold by the company. Upon completion of the sale, the group will no longer hold any interests in the target company, and the target company will no longer be a subsidiary of the group, with its assets and liabilities no longer included in the group's consolidated financial statements. DSL will acquire 100% equity of the target subsidiary and the target company.

The company will periodically conduct strategic reviews of the group's assets to enhance shareholder value. Since 2024, the group has prioritized commercial health insurance and health management businesses for development. With strong industry trends and policy support, these business segments demonstrate robust growth momentum and significantly higher gross margins compared to specialty pharmacy operations. Considering the current market conditions of the pharmacy industry and the operational performance of the target company and target subsidiary's pharmacy business, the board believes that the sale will allow the group to further focus on its core strategy, optimize resource allocation, strengthen financial support for its core business, enhance the overall gross margin of the group, and accelerate the achievement of the group's overall profit targets

### Related Stocks

- [603233.CN](https://longbridge.com/en/quote/603233.CN.md)
- [00314.HK](https://longbridge.com/en/quote/00314.HK.md)

## Related News & Research

- [Sipai Health files HKEX next-day disclosure return on share repurchase](https://longbridge.com/en/news/290549089.md)
- [Zoox to ramp up production of up to 100 newly upgraded robotaxis a week](https://longbridge.com/en/news/290748542.md)
- [09:39 ETMOHEGAN NAMED TO THE 2026 TOP 100 GLOBAL MOST LOVED WORKPLACES®](https://longbridge.com/en/news/290573702.md)
- [10:40 ETTime & Statista: Elisa among the world's 100 most sustainable companies for the third year in a row](https://longbridge.com/en/news/290581761.md)
- [SpaceX Saw 850,000 Orders From Robinhood For Its IPO: What's Going On?](https://longbridge.com/en/news/290597816.md)